Navigation Links
BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
Date:8/19/2007

ion can be found at http://www.mpsvi.com.

About Naglazyme

Naglazyme is the first and only enzyme replacement therapy indicated for the treatment of MPS VI. As the first drug approved for MPS VI, regulatory agencies in both the United States and European Union have granted Naglazyme orphan drug status, which confers seven years and 10 years of market exclusivity, respectively. Additional information can be found at http://www.naglazyme.com.

Naglazyme is indicated for patients with MPS VI. Naglazyme has been shown to improve walking and stair-climbing capacity.

The most common adverse events observed in clinical trials in Naglazyme-treated patients were headache, fever, arthralgia, vomiting, upper respiratory infections, abdominal pain, diarrhea, ear pain, cough, and otitis media. Severe reactions included angioneurotic edema, hypotension, dyspnea, bronchospasm, respiratory distress, apnea, and urticaria. The most common symptoms of infusion reactions included fever, chills/rigors, headache, rash, and mild to moderate urticaria. Nausea, vomiting, elevated blood pressure, retrosternal pain, abdominal pain, malaise, and joint pain were also reported. No patients discontinued Naglazyme infusions for adverse events and all patients that completed the double-blind portion of the trial continue to receive weekly infusions of Naglazyme. Nearly all patients developed antibodies as a result of treatment, but the level of the immune response did not correlate with the severity of adverse events or impact the improvements experienced in endurance. Because antihistamine use may increase the risk of apneic episodes, evaluation of airway patency should be considered prior to the initiation of treatment. Consideration to delay Naglazyme infusion should be given when treating patients who present with an acute febrile or respiratory illness.

About BioMar
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
2. GenoLogics Announces Bioinformatics Partnership with Illumina
3. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
4. AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results for Anti-Cancer Compound Perifosine at ASCO Meeting
5. AEterna Zentaris Partner, Spectrum, Discloses Detailed Phase 2 Data for Ozarelix, in BPH at Annual AUA Meeting
6. Inovio Biomedicals Partners to Present New Data from Two Cancer Immunotherapy Clinical Trials
7. Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Companys Investigational Drug to Treat Cocaine and Methamphetamine Addiction
8. Vical Licensee AnGes MG Announces Positive Results of Phase 3 Angiogenesis Trial in Japan
9. KineMed Presents Data Measuring Changes in Reverse Cholesterol Transport for the First Time
10. First Controlled Large-Scale Intervention Angiotensin Receptor Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study Demonstrates Significant Reduction in Blood Pressure and Protection of Organs with Valsartan
11. AEterna Zentaris Reports Positive Results with Cetrorelix in BPH for Japanese Phase 2a Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 21, 2014 Clementia Pharmaceuticals, ... Agency (EMA) has granted Orphan Medicinal Product ... candidate, for the treatment of fibrodysplasia ossificans ... disabling genetic disease characterized by painful, recurrent ... new abnormal bone formation. This process, known ...
(Date:11/21/2014)... Ontario , Nov. 20, 2014  RedRick ... mounting solutions and reading room environment guidance, has ... newest musculoskeletal radiology reading room, which may also ... designs at Penn Medicine. "In ... the American College of Radiology,s Imaging 3.0 ™ ...
(Date:11/21/2014)...   Coqui RadioPharmaceuticals Corp. , a medical isotope ... of Molybdenum-99 (Mo-99), is proud to announce it has ... design its Medical Isotope Production Facility (MIPF) in ... isotope of Technetium-99, which is used in 80 percent ... legislation making it a national priority to produce Mo-99, ...
Breaking Medicine Technology:Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 2Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 3RedRick Technologies Helps Penn Radiology Implement New Radiology Reading Room Concepts 2RedRick Technologies Helps Penn Radiology Implement New Radiology Reading Room Concepts 3Coqui RadioPharmaceuticals Inks Deal With INVAP 2
... Del., May 14, 2012  Synchrogenix Information Strategies Inc., a ... to announce the addition of a new office in ... Synchrogenix CEO, Ellen Barrosse, has appointed Bengt Olsson ... company,s newest office, located in Stockholm, Sweden.  With more ...
... 14, 2012  Eli Lilly and Company (NYSE: LLY ... its clinical oncology pipeline during the 48th Annual Meeting of ... Ill. from June 1 – 5, 2012. ... late-stage development to treat various types of cancer. The company ...
Cached Medicine Technology:Lilly Oncology To Disclose New Pipeline Data At ASCO 2012 2Lilly Oncology To Disclose New Pipeline Data At ASCO 2012 3Lilly Oncology To Disclose New Pipeline Data At ASCO 2012 4
(Date:11/23/2014)... has recently announced that its Special Friday Shoes sales, ... offer will provide ladies many gorgeous shoes at greatly discounted ... women’s dresses retailers, and its shoes include many models in ... that day: Everything at Tbdress.com is up to 90% off. ... People can use the following coupon codes as well: , ...
(Date:11/23/2014)... 21, 2014 (HealthDay News) -- Close friends have more ... group does, a new study says. "We,ve ... have an influence on individual alcohol use, but there ... peer group and the friend group,s influence on those ... School of Public Health, said in a university news ...
(Date:11/23/2014)... This evaluation provides a basic conclusion ... and manufacturing technological innovation. Then, the evaluation investigates ... in information. In this part, the evaluation provides ... and 2009-2014 market shares for each company. Through ... and Chinese suppliers finish market of Femoral Occurs ...
(Date:11/23/2014)... 23, 2014 More than two dozen ... a federal litigation involving Byetta lawsuits ( http://www.byettalawsuit2013.com/ ), ... Liebhard LLP reports. , A Case List updated ... class of Type 2 diabetes medications referred to as ... District Court, Southern District of California, where a federal ...
(Date:11/23/2014)... DC (PRWEB) November 23, 2014 “BlackVue” ... Tech Report , which features the latest and ... technology expert and reporter for NewsWatch, conducted the product ... are unique and powerful options in the car camera ... rising and it can be hard to find the ...
Breaking Medicine News(10 mins):Health News:Tbdress.com Special Friday Shoes Sales Online Now 2Health News:Close Friends May Be Key to Teens' Drinking 2Health News:Femoral Stems Industry 2014 Analysis & 2019 Forecasts for Global and Chinese Region in New Research Report at ReportsnReports.com 2Health News:Femoral Stems Industry 2014 Analysis & 2019 Forecasts for Global and Chinese Region in New Research Report at ReportsnReports.com 3Health News:Femoral Stems Industry 2014 Analysis & 2019 Forecasts for Global and Chinese Region in New Research Report at ReportsnReports.com 4Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 2Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 3Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 4Health News:A Leader in Front and Rear Facing In-Car Cameras was Featured on NewsWatch Television on October 30, 2014 2
... The distinctive ability of mothers to identify the cries ... is critical to the survival of these offspring. In ... to recognize and respond to the smiles and cries of ... and social development of these babies. We have had ...
... Tips for using the full line of dermatologist ... The Theraplex Company, the,makers of a full line ... range of dry skin conditions, is launching its ... and advice for,healthy looking and beautiful skin. Four ...
... Schizophrenia emerges from an altered pattern of brain development, ... cause the brain to develop along a path that ... article to be published in Biological Psychiatry on March ... link to schizophrenia. , A prior genetic mapping study ...
... TotalLook MammoAdvantage(TM)Provides Enhanced Image Quality, Customization ... and Workflow Benefits to Mammography ... Inc. (Nasdaq:,ICAD), an industry-leading provider of Computer-Aided Detection ... announced the,availability of the TotalLook MammoAdvantage system which ...
... can used to diagnose severity of bipolar illness , , ... blood associated with mood disorders have been identified by ... finding may change the way bipolar illness is diagnosed ... 96 patients and found varying levels of the biomarkers ...
... renters told Apartments.com, during national heart, awareness month, ... of on-site fitness facilities offered ... The majority of renters lead a healthy,lifestyle by eating ... would also,prefer to step up their current workout routine ...
Cached Medicine News:Health News:Maternal love: How a mother's brain responds to her infant 2Health News:Prepare to Unveil Yourself with Theraplex(R) for Spring and Summer 2008 2Health News:Prepare to Unveil Yourself with Theraplex(R) for Spring and Summer 2008 3Health News:Prepare to Unveil Yourself with Theraplex(R) for Spring and Summer 2008 4Health News:New genetic association with schizophrenia found by researchers 2Health News:iCAD Introduces Next-Generation TotalLook Film Digitizer 2Health News:iCAD Introduces Next-Generation TotalLook Film Digitizer 3Health News:Biomarkers for Mood May Alter Psychiatric Treatments 2Health News:National Survey Reveals Most Renters Want What They Do Not Have: On-Site Workout Facilities 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: